Abstract 35P
Background
Chemotherapy-induced alopecia is one of the most distressing symptoms for cancer patients undergoing cytotoxic chemotherapy. In this prospective two-center study, the objectives were to determine the efficacy and toxicity of a scalp-cooling device in the prevention of alopecia associated with chemotherapy.
Methods
Breast cancer patients who were planning for (neo)adjuvant chemotherapy consisting of taxane- and/or anthracycline- based regimens, with or without anti-HER2 therapy were invited to participate. They underwent a scalp cooling system offered by the Orbis Paxman Hair Loss Prevention System. The following were measured during the study: extent of hair loss based on Dean score (score ranges 0-4; 0-2 score reflects hair loss of 50% or less) 4 weeks after the completion of all cycles of chemotherapy, as determined by patients and independent assessors. Adverse events (AEs), specifically alopecia and potential study-related AEs, were graded according to NCI CTCAE v4.0.
Results
52 patients were enrolled into the study. 6 patients were excluded due to subjects’ own request (3), abnormal thyroid function (2) and anaemia (1). Of the remaining 46 patients, 50% each had taxane-based and taxane-anthracycline-based regimens. 3 of the 46 patients did not undergo any assessments after enrolment, resulting in 43 being assessable for outcomes. The median age was 51.5 years. A Dean score of 0-2 for hair loss was reported by 30.2% of the patients and 32.6% of the assessors. Only 4 patients (8.7%) did not require wearing headcover during the study. Alopecia grading were: grade 0 (9.3%), grade 1 (23.3%) and grade 2 (67.4%). Potential study-related AEs included dizziness [grade 1 (11.6%); grade 2 (2.3%)], headaches [grade 1 (4.7%)], complaint of cooling [grade 1 92.3%)]; there were no grade 3 or above toxicities.
Conclusions
In contrast to previous reports, the current scalp cooling system provided a lower efficacy in preventing alopecia in breast cancer patients also undergoing chemotherapy.
Acknowledgement: The scalp cooling system was provided by Orbis Paxman Hair Loss Prevention System.
Clinical trial identification
NCT4630080.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
602P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma
Presenter: Andrew Haydon
Session: Poster Display
Resources:
Abstract
603P - An individualised postoperative radiological surveillance schedule for IDH-wildtype glioblastoma patients (HK-GBM Registry)
Presenter: Jason Chak Yan Li
Session: Poster Display
Resources:
Abstract
604P - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status
Presenter: Marcia Brose
Session: Poster Display
Resources:
Abstract
606P - BRAF and NRAS mutations are associated with poor prognosis in Asians with acral-lentiginous and nodular cutaneous melanoma
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
607P - Single institutional outcomes of radiotherapy and systemic therapy for melanoma brain metastases in Japan
Presenter: Naoya Yamazaki
Session: Poster Display
Resources:
Abstract
608P - The efficacy of immune checkpoint inhibitors and targeted therapy in mucosal melanomas: A systematic review and meta-analysis
Presenter: Andrea Teo
Session: Poster Display
Resources:
Abstract
609P - The association between thyroid function abnormalities and vitiligo induced by pembrolizumab regarding prognosis in patients with advanced melanoma
Presenter: Moez Mobarek
Session: Poster Display
Resources:
Abstract
610P - Analyzing the clinical benefit of the evidence presented at these congresses and utilizing a standardized scale to quantify it will significantly enhance our understanding of the studies showcased, allowing for more objective evaluation and interpretation
Presenter: Charles Jeffrey Tan
Session: Poster Display
Resources:
Abstract
611P - ESMO-magnitude of clinical benefit scale (MCBS) scores for phase III trials of adjuvant and curative therapies at the 2022 ASCO annual meeting (ASCO22)
Presenter: Thi Thao Vi Luong
Session: Poster Display
Resources:
Abstract
612P - Is the juice worth the squeeze? Overall survival gain per unit treatment time as a metric of clinical benefit of systemic treatment in incurable cancers
Presenter: Vodathi Bamunuarachchi
Session: Poster Display
Resources:
Abstract